Navigation Links
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
Date:2/14/2013

alatin Technologies, Inc., such as statements about clinical trial results, potential actions by regulatory agencies including the FDA, regulatory plans, development programs, proposed indications for product candidates and market potential for product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements.  Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

 PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Statements of Operations(unaudited)Three Months Ended December 31,Six Months Ended December 31,2012201120122011REVENUES:

$
,555$
,492$
,361$
38,709OPERATING EXPENSES:Research and development

2,445,7702,693,0674,78
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... FLORHAM PARK, N.J. , March 30, 2015 ... antagonist (PAMORA) under development by Shionogi & Co., ... a phase III study (COMPOSE I) for the ... with chronic non-cancer pain receiving opioid therapy. Study ... once daily) statistically significantly improved the frequency of ...
(Date:3/29/2015)... 29, 2015  Caris Life Sciences® today announced ... Molecular Intelligence®, the company,s panomic, comprehensive tumor profiling ... several rare and difficult to treat gynecological cancers ... potential to improve patient outcomes. These studies were ... Society of Gynecologic Oncology (SGO) 2015 Annual Meeting ...
(Date:3/29/2015)... (PRWEB) March 29, 2015 As a ... often required by our pharmaceutical manufacturing clients, Whitehouse Laboratories ... sponsorship of the Berkenstock Race Team for the 2015 ... not only speed, but a strong sense of precision ... that lead to success in the quality control testing ...
(Date:3/27/2015)... , 27. März 2015  Peter Walter ... Biomedical Science für seine bahnbrechende Arbeit ausgewählt, ... Zellkompartimenten transportiert werden, sowie für die Entschlüsselung ... Reaktion auf Stress nutzen, der mit der ... ist Professor für Biochemie an der University ...
Breaking Biology Technology:Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4
... -Company,s New Name is PROLOR Biotech, Inc.- , , ... -Shareholders Approve Re-Election of Board of Directors and Other Proposals- ... (OTC Bulletin Board: MODG) today announced that shareholders approved a ... at its Annual Meeting of Shareholders held on May 21, ...
... sale in the United Statesfor treatment of pain and fever ... Cumberland Pharmaceuticals ( www.cumberlandpharma.com ) today announced ... Caldolor(TM) , an intravenous formulation of ibuprofen, through a priority ... for sale in the United States for the treatment of ...
... SEATTLE, June 11 ... results of a,large-scale Phase III study of Circadin(R) ... efficacy and safety in elderly patients.,The results were ... SLEEP,2009, the 23rd Annual Meeting of the Associated ...
Cached Biology Technology:Modigene Shareholders Approve Company Name Change and Other Proposals at Annual Meeting 2Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM) 2Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM) 3Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients 2
(Date:3/10/2015)... PROVO, Utah , March 10, 2015   ... genome interpretation, has been selected by next-generation sequencing company ... provider of whole exome and targeted gene panel interpretation. ... sequencing provider, has adopted the most current technologies to ... of genetic research. The company offers two types of ...
(Date:3/5/2015)... 5, 2015 In Brazil , ... already using these solutions and 42 percent planning to invest ... approximately 25 percent of the companies will be investing in ... majority of companies in the region are currently opting for ... model will command significant attention in the coming years. This ...
(Date:3/3/2015)... FOREST, Calif. , March 3, 2015 ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, today announced the expansion ... Cancer Research Centers, ("Fred Hutch") Clinical ...
Breaking Biology News(10 mins):PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... in the United States National Museum of Natural History ... Insects, researchers have found 16 new species of wasps ... species. The new species are described and illustrated ... a Key of the Charipinae (Hymenoptera: Cynipoidea: Figitidae) From ...
... recommendations is weak among people suffering from metabolic syndrome ... the Nordic SYSDIET study led by the University of ... high in salt and saturated fat, and too low ... have a sufficient intake of vitamin D. Metabolic syndrome ...
... can cause functional inhibition of remote regions such ... diaschisis. This phenomenon is often analyzed using positron ... these methods are expensive and radioactive. Dr. Yunjun ... Wenzhou Medical University in China quantified the changes ...
Cached Biology News:Nordic study: Few persons with metabolic syndrome adhere to nutrition recommendations 2